The nation of Zimbabwe has rejected a substantial American healthcare agreement worth $367m (272 million pounds) over five years over Washington's insistence on sensitive biological samples.
This rejection came to light after a government memo from December was leaked, which showed President Emmerson Mnangagwa believed the agreement was "skewed".
A government representative later stated that the United States was requesting biological samples for scientific study and commercial purposes but refused to guarantee the benefits from any future vaccines.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged continued talks to reach a agreement suitable to both sides so the nation's vital HIV programme can continue.
Broader Implications
This rejection comes after a similar case in neighbouring Kenya, where a high court suspended a related deal with the US after legal challenges were filed about the safety of Kenyans' medical information.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and responsibility.
According to reports, 16 nations in Africa have so far signed these new agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment via US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to provide its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"Put simply, our country would provide the raw materials for medical research without any assurance that the final treatments would be accessible to our people if a new disease outbreak emerge."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were disrupting systems previously established through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This system is intended to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how future collaboration might be arranged in a manner that honours the independence and interests of both nations."
Health Experts Response
A leading public health body said it understood the official position, but suggested that negotiations should continue considering much of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns arise, including those involving data governance or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," the group commented.
This impasse emphasises the continuing tensions between receiving vital international aid and safeguarding a country's data in an increasingly interconnected world.